Crestor vs Zetia: Head-to-Head Efficacy Compared

How These Two Drugs Work Differently

Rosuvastatin and ezetimibe lower LDL cholesterol through entirely separate pathways, which is why they are often paired rather than swapped. Understanding the mechanism clarifies why their efficacy profiles differ so sharply.

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. By blocking endogenous production, the liver upregulates LDL receptor expression, pulling more circulating LDL particles from the bloodstream. A 2003 dose-ranging study published in the American Journal of Cardiology showed that rosuvastatin 10 mg reduced LDL-C by 46% and rosuvastatin 40 mg reduced LDL-C by 55% from baseline 1. That potency made rosuvastatin the strongest available statin at equivalent doses.

Ezetimibe works at the intestinal brush border. It selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter, blocking dietary and biliary cholesterol absorption. On its own, ezetimibe 10 mg reduces LDL-C by about 18% 2. That number looks modest next to a high-intensity statin. But ezetimibe becomes clinically valuable when stacked on top of a statin, because shutting down absorption while simultaneously blocking synthesis attacks cholesterol from two directions. The 2004 ACC/AHA guidelines recognized this complementary mechanism as a rational add-on strategy 3.

A patient whose liver makes less cholesterol (statin effect) and whose gut absorbs less cholesterol (ezetimibe effect) can reach LDL targets that neither drug achieves alone.

Rosuvastatin in JUPITER: The Outcomes Evidence

JUPITER remains the definitive cardiovascular outcomes trial for rosuvastatin. The results reshaped primary prevention guidelines.

Published in the New England Journal of Medicine in 2008, the JUPITER trial enrolled 17,802 apparently healthy men and women with LDL-C <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher 4. Participants were randomized to rosuvastatin 20 mg or placebo. The trial was stopped early, at a median follow-up of 1.9 years, because of an unambiguous benefit signal.

Rosuvastatin 20 mg reduced the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56 to 95% CI 0.46 to 0.69, P<0.00001) 4. LDL-C fell by 50% and hsCRP by 37%. The number needed to treat (NNT) over two years was 95 for the primary endpoint, and 31 for any protocol-specified event.

Dr. Paul Ridker, the trial's principal investigator, stated: "These data suggest that among persons without overt cardiovascular disease but with elevated hsCRP, rosuvastatin significantly reduced the incidence of major cardiovascular events" 4. The finding extended statin benefit to a population previously considered too low-risk for pharmacotherapy.

Critics noted the early termination may have inflated the treatment effect, and the absolute risk reduction was small. Still, JUPITER directly informed the 2013 ACC/AHA guideline recommendation to consider statin therapy for individuals with hsCRP ≥2.0 mg/L even when LDL-C is below traditional thresholds 5.

Ezetimibe in IMPROVE-IT: The Add-On Evidence

IMPROVE-IT asked a different question: does adding ezetimibe to a statin reduce cardiovascular events beyond what the statin achieves alone?

Published in the New England Journal of Medicine in 2015, IMPROVE-IT randomized 18,144 patients who had been hospitalized for acute coronary syndrome (ACS) within the prior 10 days to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo 6. Median follow-up was 6 years.

The combination arm reduced LDL-C to a median of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only arm. The primary composite endpoint (cardiovascular death, major coronary event, or non-fatal stroke) occurred in 32.7% of the combination group versus 34.7% of the monotherapy group, a 6.4% relative risk reduction (HR 0.936 to 95% CI 0.89 to 0.99, P=0.016) 6.

The 2018 ACC/AHA cholesterol guideline update cited IMPROVE-IT as evidence supporting the "lower is better" LDL hypothesis and recommended ezetimibe as first-line add-on therapy when maximally tolerated statin therapy does not achieve a ≥50% LDL reduction in very high-risk patients 7. Dr. Christopher Cannon, co-principal investigator of IMPROVE-IT, noted: "IMPROVE-IT showed that adding ezetimibe to statin therapy provides an incremental clinical benefit in high-risk post-ACS patients, and further supports the concept that lower LDL is associated with fewer cardiovascular events" 6.

The absolute benefit was modest. That 2% absolute reduction over 6 years translates to an NNT of 50. But in secondary prevention, where baseline event rates are high, physicians and guidelines accepted this as clinically meaningful.

Why No Direct Head-to-Head Outcomes Trial Exists

Comparing rosuvastatin and ezetimibe head-to-head is a question that sounds obvious but misses how these drugs are used clinically.

No sponsor has funded a large randomized outcomes trial pitting rosuvastatin against ezetimibe as monotherapies. The reason is practical: guidelines position them in different tiers. High-intensity statins (rosuvastatin 20 to 40 mg, atorvastatin 40 to 80 mg) are first-line therapy for patients meeting ASCVD risk thresholds. Ezetimibe is a second-line agent, added when the statin alone cannot drive LDL low enough 7.

Designing a trial that withholds a statin from eligible patients to test ezetimibe alone would raise ethical concerns. And a trial giving both drugs as monotherapy to low-risk patients would need an enormous sample size to detect a difference in hard endpoints, given the low baseline event rate.

Smaller surrogate-endpoint studies have compared the two drugs on LDL lowering. A 2004 trial by Ballantyne and colleagues (N=2,579) compared rosuvastatin 10 mg to ezetimibe 10 mg plus atorvastatin 10 mg, finding that the combination matched or exceeded rosuvastatin's LDL reduction depending on the statin dose used in the combination arm 8. That study confirmed ezetimibe's additive value but did not test ezetimibe as a standalone competitor.

A Decision Framework: When Clinicians Choose Which Drug

The choice between rosuvastatin and ezetimibe is rarely an either/or decision. It follows a clinical algorithm.

Start with rosuvastatin (or another high-intensity statin) when:

• 10-year ASCVD risk is ≥7.5% and the patient has no contraindication to statins
• The patient has established ASCVD (secondary prevention)
• LDL-C is ≥190 mg/dL (familial hypercholesterolemia phenotype)
• The patient has diabetes and is aged 40 to 75 with LDL-C ≥70 mg/dL

The 2018 ACC/AHA guideline assigns rosuvastatin 20 to 40 mg as a high-intensity statin expected to lower LDL-C by ≥50% 7.

Add ezetimibe when:

• Maximally tolerated statin therapy does not achieve a ≥50% LDL-C reduction
• LDL-C remains ≥70 mg/dL in very high-risk ASCVD patients despite high-intensity statin
• The patient has a partial statin intolerance and needs additional LDL lowering from a non-statin mechanism

Use ezetimibe as monotherapy only when:

• The patient has documented statin intolerance across multiple agents (true in roughly 5 to 10% of patients attempting statin therapy, per a 2015 meta-analysis) 9
• The patient refuses statin therapy after shared decision-making

In the monotherapy scenario, ezetimibe delivers about an 18% LDL reduction. That is far less than rosuvastatin's 45 to 55%. But 18% is better than zero. And for patients who cannot tolerate any statin dose, ezetimibe provides a mechanism-of-action that does not involve the mevalonate pathway responsible for most statin-related myalgias.

LDL-Lowering Potency: The Numbers Side by Side

Quantifying the LDL gap between these two drugs makes the efficacy difference concrete.

Rosuvastatin's dose-response curve is well characterized. In the STELLAR trial (N=2,431), rosuvastatin at 10 mg, 20 mg, and 40 mg reduced LDL-C by 46%, 52%, and 55%, respectively, over 6 weeks 10. By comparison, atorvastatin 10 mg reduced LDL-C by 37% and atorvastatin 80 mg by 51% in the same trial. Rosuvastatin 10 mg outperformed atorvastatin 20 mg on a milligram-for-milligram basis.

Ezetimibe 10 mg as monotherapy reduces LDL-C by approximately 18%. When added to an ongoing statin, ezetimibe delivers an incremental 23 to 24% reduction beyond what the statin achieves alone 2. That additive effect is not trivial. A patient on rosuvastatin 20 mg (52% LDL reduction) who adds ezetimibe can expect a combined reduction approaching 60 to 65%.

For a patient starting with an LDL-C of 160 mg/dL:

• Rosuvastatin 20 mg alone would bring LDL-C to approximately 77 mg/dL
• Ezetimibe 10 mg alone would bring LDL-C to approximately 131 mg/dL
• Rosuvastatin 20 mg plus ezetimibe 10 mg would bring LDL-C to approximately 58 mg/dL

Those numbers explain why every major guideline positions ezetimibe as an adjunct rather than an alternative to high-intensity statins. The gap in LDL-lowering power is roughly threefold.

Beyond LDL: Effects on Other Lipid Markers

LDL-C is the primary target, but both drugs affect the broader lipid panel differently.

Rosuvastatin reduces triglycerides by 10 to 35% and raises HDL-C by 8 to 14%, depending on dose and baseline triglyceride levels 10. In JUPITER, the median triglyceride reduction was 17% 4. Statins also modestly reduce apolipoprotein B (apoB) and lipoprotein(a), though the clinical significance of the Lp(a) reduction remains debated.

Ezetimibe has minimal independent effect on triglycerides (reductions of 1 to 8%) and raises HDL-C by only 1 to 3% 2. Its primary action is confined to LDL-C and total cholesterol. Ezetimibe does reduce apoB modestly, by about 15%, reflecting fewer circulating atherogenic particles.

For patients with mixed dyslipidemia (elevated LDL-C plus elevated triglycerides), rosuvastatin provides broader lipid correction. For patients whose isolated problem is LDL-C above goal despite statin therapy, ezetimibe's targeted mechanism adds value without affecting triglyceride management.

Safety and Side-Effect Profiles

Both drugs carry generally favorable safety records, but the side-effect profiles differ in character and frequency.

Rosuvastatin's most common adverse effects are myalgias (reported in 2 to 11% of clinical trial participants, though nocebo-controlled studies suggest the true drug-attributable rate is closer to 1 to 2%), transaminase elevations (0.2 to 0.4%), and a small increase in the incidence of new-onset diabetes 11. In JUPITER, rosuvastatin was associated with a physician-reported diabetes rate of 3.0% versus 2.4% in the placebo group (P=0.01) over 1.9 years 4. The risk appears concentrated in patients with pre-existing metabolic syndrome or impaired fasting glucose.

Ezetimibe is one of the best-tolerated lipid-lowering agents available. In pooled analyses, the rate of adverse events with ezetimibe was comparable to placebo 2. Myalgia rates did not differ from placebo. Hepatotoxicity is rare. The most common complaints are mild gastrointestinal symptoms (diarrhea, abdominal discomfort) in <4% of patients 12.

For patients who experience statin-related muscle symptoms, ezetimibe offers a well-tolerated alternative pathway for LDL reduction without the mevalonate pathway inhibition that drives most statin myopathy.

Cost and Access Considerations

Both rosuvastatin and ezetimibe are available as generics, which has narrowed the cost gap considerably since their patent expirations.

Generic rosuvastatin typically costs $4 to $15 per month at major U.S. pharmacy chains. Generic ezetimibe runs $8 to $20 per month. The branded versions (Crestor and Zetia) remain available but are rarely dispensed given the generic alternatives. Most commercial insurance plans and Medicare Part D formularies cover both generics at Tier 1 or Tier 2 copay levels.

When ezetimibe is added to a statin, the monthly pill cost approximately doubles. The combination tablet ezetimibe/simvastatin (generic Vytorin) is available for patients who prefer a single pill, though no fixed-dose combination of ezetimibe with rosuvastatin is currently FDA-approved. Patients on rosuvastatin plus ezetimibe take two separate tablets daily.

Where PCSK9 Inhibitors Fit in the Hierarchy

If rosuvastatin plus ezetimibe still leaves LDL-C above goal, PCSK9 inhibitors (evolocumab, alirocumab) become the next consideration.

The 2018 ACC/AHA guideline recommends a stepwise approach for very high-risk ASCVD patients: maximize statin intensity first, add ezetimibe second, and consider a PCSK9 inhibitor third 7. The FOURIER trial (N=27,564) demonstrated that evolocumab, added to statin therapy, reduced the primary composite endpoint by 15% (HR 0.85, P<0.001) and lowered LDL-C by 59% from a median baseline of 92 mg/dL 13. Ezetimibe sits between statins and PCSK9 inhibitors in both efficacy and cost, making it the logical second step before escalating to injectable therapy.

For most patients, rosuvastatin plus ezetimibe achieves an LDL-C reduction of 60 to 65%, which is sufficient to reach the <70 mg/dL target. Only those with very high baseline LDL or familial hypercholesterolemia typically require a PCSK9 inhibitor on top of dual oral therapy.